編號,通報時間,中文品名,英文品名,許可證字號,成分學名,劑型劑量,許可證持有藥商,短缺原因,評估結果及建議
"1","20140916","無","BCG Immunotherapeutic Immuncyst","衛署菌疫輸字第000369號","Bacillus of Calmette and Guerin","2-8 x 108 CFU/vial","賽諾菲股份有限公司","產能問題","1. 主成分為Bacillus Calmette-Guerin(簡稱BCG)，適應症為治療及預防膀胱原發或復發性原位癌或經尿道切除後之表淺性乳頭瘤（ＴＡ及Ｔ１）。 2. BCG免疫療法在初期膀胱癌的治療與預防復發佔有重要之角色，且目前仍無證據顯示使用其他化學藥物治療會比BCG有更佳之治療效果，臨床使用上BCG仍具無可替代性。 3. 賽諾菲股份有限公司因產能問題，發生短缺，建議以國外其他廠牌之BCG替代。"
"2","20140923","＂綠洲＂ 維他命Ａ眼藥膏","VITA A EYE OINTMENT ＂OASIS＂","衛署藥製字第004156號","VITAMIN A","3.5g","綠洲化學工業有限公司","與PIC/S相關","維他命A眼藥膏雖然臨床上可改以其他不同成分藥物替代治療(DURATEARS OPH/Duratears Oph Ointment 、JEN SHENG Super Eye Lotion)，但是治療效果仍以維他命A眼藥膏較佳，已啟動缺藥處理機制"
"3","20150104","血基賞濃縮輸注液 25 毫克/毫升","Normosang","衛署罕菌疫輸字第000010號","Human Hemin","10ml/Amp ,4 Amp/盒","科懋生物科技股份有限公司","因健保署重新核價, 不敷成本廠商無法進口","目前持續供貨，基於廠商仍與健保署協商中，持續追蹤 。必要時啟動處理機制。"
"4","20150212","非尼乙非林點眼液１０％（鹽酸去甲　麻黃　）","Phenylephrine","衛署藥製字第030859號","Phenylephrine","10%/5ml eye drops","五福化學製藥廠有限公司","與PIC/S相關","建議啟動缺藥處理機制，持續追蹤五福及綠洲藥廠何時通過PIC/S。"
"5","20150212","普樂他諾－Ｌ針","PROTERNOL L INJECTION","衛署藥輸字第012225號","ISOPROTERENOL HCL","注射劑","宜泰貿易有限公司","停產或停止進口","建議啟動缺藥處理機制，專案進口該藥物，提供臨床使用。"
